Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> Jefferies Raises TP for CSPC Pharmaceutical Group (01093.HK) to HKD7.2, Maintains 'Underperform' Rating
Recommend 6 Positive 12 Negative 5 |
||||
|
||||
|
Jefferies published a research report stating that CSPC Pharmaceutical Group (01093.HK) still faced pressure in its performance last year, with annual revenue declining by 10% year-on-year to RMB260 billion, which was below expectations. Although management expects the finished drug business to return to positive growth this year, the market is concerned about potential Volume-Based Procurement (VBP) risks, including the possible inclusion of Irinotecan Hydrochloride Liposome Injection in the national VBP. Jefferies believes that the adverse factors of VBP are expected to persist this year. While Business Development (BD) is crucial, the market continues to bet on stock prices based on prepayment expectations, and with expectations being raised, the risk of disappointment is increasing. The firm maintains an 'Underperform' rating for CSPC but raises the target price from HKD5.9 to HKD7.2. (hc/w) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
URL: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
